Nanoselenium combined with glutamine versus glutamine alone for sepsis

Nanoselenium combined with glutamine versus Glutamine alone for Sepsis (NGS): a randomized controlled trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN88007295

Enrollment

120

Registered

2026-01-06

Start date

2026-01-15

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis Infections and Infestations

Interventions

Eligible patients will be randomized to receive either the intervention or control in a 1:1 allocation ratio. The random allocation sequence will be generated by an independent statistician using comp

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Age =18 years old 2. Sepsis (as defined by Sepsis-3) 3. Expected to be admitted to the ICU for more than 48 hours

Exclusion criteria

Exclusion criteria: 1. Refusal to participate or failure to provide informed consent 2. Pregnancy or breastfeeding 3. Known allergy to selenium or glutamine 4. Malignancy 5. Severe hepatic or renal dysfunction (including liver failure or dialysis-dependent uremia) 6. Receipt of immunosuppressive therapy or organ transplantation within the past 6 months 7. Fasting

Countries

China

Contacts

Public ContactWan-Jie Gu

guwanjie@jnu.edu.cn+86 (0)15850546835

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026